AANS Neurosurgeon | Volume 27, Number 3, 2018


A Novel Anti-Cancer Chemotherapeutic Agent Inhibits Glioblastoma Growth and Radiation Resistance

This potential chemotherapeutic agent to treat glioblastoma is a novel small molecule inhibitor.


Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells — glioma stem cells — is responsible for glioblastoma’s tumorigenesis, treatment resistance and subsequent tumor recurrence.

A collaborative team of neuro-oncology surgeon/scientists — led by Ichiro Nakano, M.D., Ph.D., University of Alabama at Birmingham, and Maode Wang, M.D., Xi’an Jiaotong University, Xi’an, China — has discovered a unique and previously unidentified molecular mechanism that maintains glioma stem cells, and they have tested it as a potential therapeutic target in glioblastoma, using a novel small molecule inhibitor they designed and synthesized.

Click here to read more.

Comments are closed.